Last Updated: Jan 15 2009 - Able2Act


Fact Sheet for Purdue Pharma L.P.

Country: USA
Contact: Purdue Pharma L.P.One Stamford ForumStamford, CT 06901 United States
Homepage: http://www.purduepharma.com
Comments: Purdue Pharma offers Cost-free training and educational materials regarding prescription drug abuse and diversion.
Compilation by Silobreaker
Although Silobreaker has relied on what it regards as reliable sources while compiling the content herein, Silobreaker cannot guarantee the accuracy, completeness, integrity or quality of such content and no responsibility is accepted by Silobreaker in respect of such content. Readers must determine for themselves what reliance they should place on the compiled content herein.

Related Stories

First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Risk based monitoring: Where is it today?

At Partnerships in Clinical Trials,Alison Taber, Vice President, Global Data Management, at Theorem Clinical Research and Mitchell Katz, Executive Director, Medical Research Operations, Purdue Pharma L.P sat down with Metidata to discuss the the panel ... [Published Partnerships in Clinical Trials - Apr 22 2014]
First reported Apr 20 2014 - Updated Apr 20 2014 - 1 reports

2 men sought in 11 Phoenix-area armed robberies

PHOENIX - Authorities are looking for two men allegedly connected to 11 armed robberies across the Phoenix metro, according to Silent Witness.Officials said the two men robbed at least 11 independent pharmacies in Phoenix, Gilbert, Tempe, Scottsdale and ... [Published ABC15.com - Apr 20 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Fibromyalgia: A Clinical Review

Corresponding Author: Daniel J. Clauw, MD, University of Michigan, 24 Frank Lloyd Wright Dr, PO Box 385, Ann Arbor, MI 48106 ( dclauw@med.umich.edu ).Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure ... [Published Journal of the American Medical Association - Apr 15 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 2 reports

Research and Markets: Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7jfkk5/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & ... [Published Business Wire Health News - Apr 11 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Doctor’s must help stem painkiller epidemic

One of the most difficult challenges any primary care physician faces is the treatment of chronic pain. Each patient and situation is unique. I’ve seen terminal cancer patients trying to live out their last days comfortably, people struggling all their ... [Published Santa Fe New Mexican - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Research Highlights Risk For Acetaminophen Toxicity From Use Of Over The Counter And Prescription Pain Medications

STAMFORD, Conn.Acetaminophen is a commonly used pain reliever that is available in over the counter products (Tylenol®) and prescription medications, where it is combined with opioid analgesics (i.e., fixed-dose combination products). For example, acetaminophen ... [Published TheStreet.com - Apr 04 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Kolltan Pharmaceuticals Raises $60M Series D for Biologic Cancer Drug

(c) 2014 Dow Jones & Company, Inc.Kolltan Pharmaceuticals Inc ., a company developing biologics that target receptor tyrosine kinases in a bid to halt the growth of cancer and other diseases, has raised a $60 million Series D round to push the company's ... [Published Dow Jones Financial Information Services - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

US Pharmaceutical Companies Hide Drug Risks for Profit

Evidence shows that pharmaceutical companies hide the dangerous side effects of their new drugs in order to make as much profit as possible before their patents run out Martha Rosenberg reports for Alternet. Companies like Merck, Johnson & Johnson, and ... [Published Project Censored - Mar 25 2014]
First reported Mar 20 2014 - Updated Mar 21 2014 - 2 reports

Purdue Pharma Announces Positive Phase 3 Clinical Trial Results of Hydrocodone Bitartrate ER Tablets

– Purdue Pharma L.P. announced that a Phase 3 study of an investigational extended-release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once-daily analgesic ... [Published Drugs.com - Mar 21 2014]
First reported Mar 13 2014 - Updated Mar 13 2014 - 1 reports

OxyContin maker plans abuse-resistant hydrocodone drug March 13, 2014

WASHINGTON – The maker of OxyContin says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, a surprise development that could derail sales of the recently launched Zohydro, a similar medication that has been criticized ... [Published Spokesman-Review.com - Mar 13 2014]
Entities: Vicodin, OxyContin, Zohydro
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Purdue Pharma L.P. Announces Positive Phase 3 Clinical Trial Results of Once-Daily Hydrocodone Bitartrate Extended-Release Tablets

STAMFORD, Conn., March 12, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that a Phase 3 study of an investigational extended-release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low ... [Published PR Newswire: Health - Mar 12 2014]
First reported Jan 27 2014 - Updated Jan 27 2014 - 1 reports

Purdue Pharma L.P. Names Mark Timney President and Chief Executive Officer

STAMFORD, Conn., Jan. 27, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that the company's Board of Directors has appointed Mark Timney as President and Chief Executive Officer."We found a proven leader in Mark Timney," said Dr. Raymond Sackler, ... [Published PR Newswire: Health - Jan 27 2014]
In Focus
Network
Network

Blogs

sort by: Date | Relevance
Purdue Pharma L.P. Names Mark Timney President ... [Published PR Newswire: Health - Jan 27 2014]
STAMFORD, Conn., Jan. 27, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that the company's Board of Directors has appointed Mark Timney as President and Chief Executive Officer."We found a proven leader in Mark Timney," said Dr. Raymond Sackler, ...
Purdue Pharma L.P. Announces Positive Phase 3 C... [Published PR Newswire: Health - Mar 12 2014]
STAMFORD, Conn., March 12, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that a Phase 3 study of an investigational extended-release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low ...
Research and Markets: Global Pain Management Dr... [Published Business Wire Health News - Apr 11 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7jfkk5/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & ...
Risk based monitoring: Where is it today? [Published Partnerships in Clinical Trials - Apr 22 2014]
At Partnerships in Clinical Trials,Alison Taber, Vice President, Global Data Management, at Theorem Clinical Research and Mitchell Katz, Executive Director, Medical Research Operations, Purdue Pharma L.P sat down with Metidata to discuss the the panel ...
Purdue Pharma Petitions FDA to Apply ER/LA Requ... [Published FDA Law Blog - Feb 23 2014]
By Alexander J. Varond –Purdue Pharma recently submitted a citizen petition challenging FDA’s decision to require labeling revisions and postmarket study requirements for extended-release and long acting opioid analgesic products but not immediate-release ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.